Kevin Judice, DICE Therapeutics CEO
October 11, 2022 11:06 AM EDTUpdated October 12, 09:21 AM
R&D

Up­dat­ed: DICE rolls on as lead oral IL-17 can­di­date meets proof-of-con­cept in PhI tri­al, send­ing shares high­er

Paul Schloesser

Associate Editor

DICE Ther­a­peu­tics is now mov­ing for­ward on the next stage of clin­i­cal de­vel­op­ment for its IL-17 can­di­date, on the heels of tout­ing a Phase I …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times